Quotient Therapeutics

News

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

R&D

Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.